Overview of surfactant replacement trials - PubMed (original) (raw)
Review
. 2005 May:25 Suppl 2:S40-4.
doi: 10.1038/sj.jp.7211320.
Affiliations
- PMID: 15861172
- DOI: 10.1038/sj.jp.7211320
Review
Overview of surfactant replacement trials
Gautham K Suresh et al. J Perinatol. 2005 May.
Abstract
Clinical trials have evaluated the overall efficacy of surfactant therapy, as well as the relative efficacy of different surfactant preparations, the optimal timing of administration and the optimal dosage. Surfactant therapy leads to significant clinical improvement in infants at risk for, or having, respiratory distress syndrome (RDS). Clinical trials that compared the effects of synthetic or animal-derived surfactant preparations to placebo or no therapy demonstrate that surfactant therapy lead to rapid improvement in oxygenation, decreased ventilator support, decreased risk of pneumothorax, and mortality. Earlier treatment, prophylactic treatment of infants at high risk of developing RDS, and selective re-treatment leads to improved clinical outcome as well. Currently available animal-derived surfactants are superior to non-protein-containing synthetic surfactants. Ongoing evaluation will determine if important differences in animal-derived products are noted. Future trials will evaluate third-generation surfactant products and further refine what constitutes optimal use of surfactant.
Similar articles
- Animal-derived surfactants versus past and current synthetic surfactants: current status.
Moya F, Maturana A. Moya F, et al. Clin Perinatol. 2007 Mar;34(1):145-77, viii. doi: 10.1016/j.clp.2006.12.005. Clin Perinatol. 2007. PMID: 17394936 Review. - Surfactant and respiratory distress syndrome.
Milner AD. Milner AD. Turk J Pediatr. 1996 Jan-Mar;38(1):37-43. Turk J Pediatr. 1996. PMID: 8819619 Review. - Neonatal respiratory distress syndrome and surfactant therapy; a brief review.
Robertson B. Robertson B. Eur Respir J Suppl. 1989 Mar;3:73s-76s. Eur Respir J Suppl. 1989. PMID: 2662999 Review. - [Exogenous surfactant therapy: new synthetic surfactants].
Lacaze-Masmonteil T. Lacaze-Masmonteil T. Arch Pediatr. 2008 Jun;15 Suppl 1:S42-6. doi: 10.1016/S0929-693X(08)73946-0. Arch Pediatr. 2008. PMID: 18822258 French.
Cited by
- Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies).
Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Costeloe KL, et al. BMJ. 2012 Dec 4;345:e7976. doi: 10.1136/bmj.e7976. BMJ. 2012. PMID: 23212881 Free PMC article. - Association of Adherence to Surfactant Best Practice Uses With Clinical Outcomes Among Neonates in Sweden.
Challis P, Nydert P, Håkansson S, Norman M. Challis P, et al. JAMA Netw Open. 2021 May 3;4(5):e217269. doi: 10.1001/jamanetworkopen.2021.7269. JAMA Netw Open. 2021. PMID: 33950208 Free PMC article. - Enhanced surfactant adsorption via polymer depletion forces: a simple model for reversing surfactant inhibition in acute respiratory distress syndrome.
Stenger PC, Zasadzinski JA. Stenger PC, et al. Biophys J. 2007 Jan 1;92(1):3-9. doi: 10.1529/biophysj.106.091157. Epub 2006 Oct 13. Biophys J. 2007. PMID: 17040987 Free PMC article. - Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability.
Zasadzinski JA, Stenger PC, Shieh I, Dhar P. Zasadzinski JA, et al. Biochim Biophys Acta. 2010 Apr;1798(4):801-28. doi: 10.1016/j.bbamem.2009.12.010. Epub 2009 Dec 22. Biochim Biophys Acta. 2010. PMID: 20026298 Free PMC article. Review. - Prevention of Chronic Morbidities in Extremely Premature Newborns with LISA-nCPAP Respiratory Therapy and Adjuvant Perinatal Strategies.
Balázs G, Balajthy A, Seri I, Hegyi T, Ertl T, Szabó T, Röszer T, Papp Á, Balla J, Gáll T, Balla G. Balázs G, et al. Antioxidants (Basel). 2023 May 24;12(6):1149. doi: 10.3390/antiox12061149. Antioxidants (Basel). 2023. PMID: 37371878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources